Fidelis Capital Partners LLC Invests $175,000 in Alnylam Pharmaceuticals, Inc. $ALNY

Fidelis Capital Partners LLC bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 536 shares of the biopharmaceutical company’s stock, valued at approximately $175,000.

A number of other large investors have also recently bought and sold shares of the stock. SVB Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals in the first quarter worth $27,000. Atlantic Union Bankshares Corp purchased a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth about $30,000. Ameritas Advisory Services LLC acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at about $42,000. AlphaQuest LLC acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at about $43,000. Finally, Larson Financial Group LLC lifted its holdings in Alnylam Pharmaceuticals by 77.7% in the 1st quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 87 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ALNY. Bank of America lifted their price target on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. Evercore ISI lifted their target price on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research note on Thursday, September 11th. Morgan Stanley boosted their price target on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a report on Monday, October 6th. Wells Fargo & Company raised their price objective on Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a report on Tuesday. Finally, Jefferies Financial Group dropped their target price on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a research note on Thursday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $482.17.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 3,022 shares of the firm’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $451.48, for a total value of $1,364,372.56. Following the transaction, the executive vice president directly owned 20,221 shares of the company’s stock, valued at $9,129,377.08. This trade represents a 13.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 8,924 shares of the company’s stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $4,034,094.20. Following the completion of the sale, the chief executive officer directly owned 65,409 shares of the company’s stock, valued at $29,568,138.45. The trade was a 12.01% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 98,144 shares of company stock worth $44,160,261 in the last quarter. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Stock Up 2.3%

Shares of NASDAQ:ALNY opened at $451.95 on Wednesday. The stock has a 50-day simple moving average of $458.75 and a 200-day simple moving average of $380.73. The stock has a market capitalization of $59.71 billion, a P/E ratio of -182.98 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $1.51. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $1.25 billion for the quarter, compared to analysts’ expectations of $943.37 million. During the same period in the previous year, the company posted ($0.50) earnings per share. Alnylam Pharmaceuticals’s revenue was up 149.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.